20-HETE induces hyperglycemia through the cAMP/PKA-PhK-GP pathway

Area of Science:

• Biochemistry
• Endocrinology
• Metabolic Research

Background:

• Cytochrome P450 4F2 (CYP4F2) produces 20-hydroxyeicosatetraenoic acid (20-HETE), previously linked to elevated blood pressure.
• The impact of 20-HETE on glucose metabolism remained largely uncharacterized.

Purpose of the Study:

• To investigate the effect of hepatic CYP4F2 overexpression and subsequent high 20-HETE production on glucose metabolism.
• To elucidate the specific molecular pathways involved in 20-HETE-induced metabolic alterations.

Main Methods:

• Generation of CYP4F2 transgenic mice with high hepatic 20-HETE production.
• Measurement of plasma glucose, insulin, hepatic CYP4F2 expression, and 20-HETE levels.
• Assessment of glycogen phosphorylase (GP) activity and the cAMP/protein kinase A (PKA)-phosphorylase kinase (PhK)-GP pathway.
• In vitro studies using Bel7402 cells and a selective 20-HETE inhibitor.

Main Results:

• Transgenic mice exhibited elevated hepatic 20-HETE and fasting plasma glucose, with normal insulin levels.
• Increased glycogen phosphorylase activity and activation of the cAMP/PKA-PhK-GP pathway were observed in transgenic mice.
• Administration of a 20-HETE inhibitor normalized these metabolic parameters.
• 20-HETE did not impair insulin signaling in hepatic cells, indicating insulin sensitivity was maintained.

Conclusions:

• Hepatic 20-HETE contributes to hyperglycemia through activation of the cAMP/PKA-PhK-GP pathway.
• The observed hyperglycemia in CYP4F2 transgenic mice is not due to insulin resistance or dysfunction.
• These findings highlight a novel role for 20-HETE in regulating glucose homeostasis.